Drug Trial Radar · NCT03383081
The Safety/Efficacy of hUC Mesenchymal Stem Cells(19#iSCLife®-OA) Therapy for Patients With Osteoarthritis
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Oct 1, 2018
Primary completion
Dec 31, 2026
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Sclnow Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 26, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is verify the efficacy and safety of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) therapy for patients with Osteoarthritis, and in addition, provide basis for exploring the treatment regimen of UC-MSC therapy in different degree of cartilage defect disease
Conditions
- Osteoarthritis, Knee
Interventions
Low dose mesenchymal stem cellsBiological
Human umbilical cord mesenchymal stem cells (SCLnow 19#): group A, 1 \* 10\^7 cells (5ml);
High dose mesenchymal stem cellsBiological
Human umbilical cord mesenchymal stem cells (SCLnow 19#): group B, 2 \* 10\^7 cells (5ml)
Intraarticular injectionProcedure
Intraarticular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#) with different dose group
Primary outcomes
What the sponsor says the trial is designed to measure.
- Kellgren-Lawrence Grading ScaleTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xiangya Hospital Central South University
Changsha, Hunan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.